Literature DB >> 15343377

Why does diabetes increase atherosclerosis? I don't know!

Ira J Goldberg1.   

Abstract

There is a wealth of clinical data showing the relationship between diabetes mellitus and atherosclerosis and its clinical complications. To dissect this relationship, investigators have attempted, usually unsuccessfully, to create a small-animal model in which diabetes accelerates vascular lesion development. This effort has often been complicated by development of hyperlipidemia leading to difficulty in differentiating the effects of hyperglycemia from those of lipid abnormalities. A study in the current issue of the JCI provides data on a new mouse model in which atherosclerosis initiation is accelerated in diabetic mice and is reduced by insulin therapy. Moreover, these animals have greater intra-arterial hemorrhage, which might be due to less stable plaques.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15343377      PMCID: PMC514600          DOI: 10.1172/JCI22826

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

Review 1.  Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.

Authors:  S M Grundy; I J Benjamin; G L Burke; A Chait; R H Eckel; B V Howard; W Mitch; S C Smith; J R Sowers
Journal:  Circulation       Date:  1999-09-07       Impact factor: 29.690

2.  Biochemistry and molecular cell biology of diabetic complications.

Authors:  M Brownlee
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

3.  Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state.

Authors:  S M Haffner; L Mykkänen; A Festa; J P Burke; M P Stern
Journal:  Circulation       Date:  2000-03-07       Impact factor: 29.690

4.  Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

Authors:  R C Turner; H Millns; H A Neil; I M Stratton; S E Manley; D R Matthews; R R Holman
Journal:  BMJ       Date:  1998-03-14

5.  Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet.

Authors:  S Merat; F Casanada; M Sutphin; W Palinski; P D Reaven
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-05       Impact factor: 8.311

6.  Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice.

Authors:  P Reaven; S Merat; F Casanada; M Sutphin; W Palinski
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-10       Impact factor: 8.311

7.  Effect of hyperglycemia and hyperlipidemia on atherosclerosis in LDL receptor-deficient mice: establishment of a combined model and association with heat shock protein 65 immunity.

Authors:  P Keren; J George; A Shaish; H Levkovitz; Z Janakovic; A Afek; I Goldberg; J Kopolovic; G Keren; D Harats
Journal:  Diabetes       Date:  2000-06       Impact factor: 9.461

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Increased atherosclerosis in streptozotocin-induced diabetic mice.

Authors:  V V Kunjathoor; D L Wilson; R C LeBoeuf
Journal:  J Clin Invest       Date:  1996-04-01       Impact factor: 14.808

10.  Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial.

Authors: 
Journal:  Am J Cardiol       Date:  1995-05-01       Impact factor: 2.778

View more
  26 in total

1.  Elevated Glucose Levels Promote Contractile and Cytoskeletal Gene Expression in Vascular Smooth Muscle via Rho/Protein Kinase C and Actin Polymerization.

Authors:  Tran Thi Hien; Karolina M Turczyńska; Diana Dahan; Mari Ekman; Mario Grossi; Johan Sjögren; Johan Nilsson; Thomas Braun; Thomas Boettger; Eliana Garcia-Vaz; Karin Stenkula; Karl Swärd; Maria F Gomez; Sebastian Albinsson
Journal:  J Biol Chem       Date:  2015-12-18       Impact factor: 5.157

Review 2.  Type 2 diabetes, mitochondrial biology and the heart.

Authors:  Michael N Sack
Journal:  J Mol Cell Cardiol       Date:  2009-02-13       Impact factor: 5.000

3.  Hepatic transforming growth factor-β 1 stimulated clone-22 D1 controls systemic cholesterol metabolism.

Authors:  Julia Jäger; Vera Greiner; Daniela Strzoda; Oksana Seibert; Katharina Niopek; Tjeerd P Sijmonsma; Michaela Schäfer; Allan Jones; Roldan De Guia; Marc Martignoni; Geesje M Dallinga-Thie; Mauricio B Diaz; Thomas G Hofmann; Stephan Herzig
Journal:  Mol Metab       Date:  2014-01-08       Impact factor: 7.422

Review 4.  Insulin resistance and pancreatic beta cell failure.

Authors:  Masato Kasuga
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

5.  Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products.

Authors:  Bo Feng; Lei Xu; Hua Wang; Xinfeng Yan; Junli Xue; Fengjing Liu; Ji-Fan Hu
Journal:  Biochim Biophys Acta       Date:  2011-05-30

6.  DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.

Authors:  Nga N Ta; Corinne A Schuyler; Yanchun Li; Maria F Lopes-Virella; Yan Huang
Journal:  J Cardiovasc Pharmacol       Date:  2011-08       Impact factor: 3.105

7.  Diabetes with poor glycaemic control does not promote atherosclerosis in genetically modified hypercholesterolaemic minipigs.

Authors:  Rozh H Al-Mashhadi; Martin M Bjørklund; Martin B Mortensen; Christina Christoffersen; Torben Larsen; Erling Falk; Jacob F Bentzon
Journal:  Diabetologia       Date:  2015-05-31       Impact factor: 10.122

8.  Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties.

Authors:  A Hoang; A J Murphy; M T Coughlan; M C Thomas; J M Forbes; R O'Brien; M E Cooper; J P F Chin-Dusting; D Sviridov
Journal:  Diabetologia       Date:  2007-06-20       Impact factor: 10.122

Review 9.  Genetics of macrovascular complications in diabetes.

Authors:  Frédéric Fumeron; André F Reis; Gilberto Velho
Journal:  Curr Diab Rep       Date:  2006-04       Impact factor: 4.810

10.  The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.

Authors:  A C Calkin; S Giunti; K J Sheehy; C Chew; V Boolell; Y S Rajaram; M E Cooper; K A Jandeleit-Dahm
Journal:  Diabetologia       Date:  2008-07-02       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.